HIV-derived antibacterial shows promise against drug-resistant bacteria

June 19, 2013

A team of researchers at the University of Pittsburgh has developed antibacterial compounds, derived from the outer coating of HIV, that could be potential treatments for drug-resistant bacterial infections and appear to avoid generating resistance. These new agents are quite small, making them inexpensive and easy to manufacture. The research was published in the June 2013 issue of the journal Antimicrobial Agents and Chemotherapy.

The first of many probable applications will likely be the chronic bacterial infections in the lungs of "that frequently develop resistance to all standard antibiotics, and are the leading cause of death in these patients," says senior author Ronald Montelaro.

The lead compound shows powerful antibacterial activity against clinical isolates of diverse that are resistant to most antibiotics. These agents, called engineered cationic (eCAPs) "may be applicable to treatment of other respiratory infections, topical infections, and systemic infections," says Montelaro.

The genesis of the new agent was basic research on HIV envelope protein structure and function, says Montelaro. As part of this research, "we identified highly conserved unique that were predicted by computer modeling to assume structures characteristic of natural antibacterial peptides. Since antibacterial peptides specifically target and disrupt the integrity and function of bacterial membranes, we thought that these similar in the HIV envelope protein might contribute to toxicity and death in infected cells by altering cell membranes."

The team engineered the original HIV peptides for greater effectiveness and smaller size, the latter to reduce manufacturing expenses. The engineering involved modifying amino acid content (they contain just two different amino acids), peptide length, charge, and hydrophobicity. The current paper describes the third generation peptides. The lead agent contains just 12 amino acid residues.

"Another potential application is biodefense, where eCAPs may be used as a rapid postexposure aerosol treatment in individuals after exposure to aerosolized pathogens, where the goal of immediate treatment would be to rapidly reduce bacterial dose from a lethal to a nonlethal or subclinical level," says Montelaro.

Explore further: Discovery holds potential in destroying drug-resistant bacteria

Related Stories

Discovery holds potential in destroying drug-resistant bacteria

May 7, 2013
Through the serendipity of science, researchers at the University of Pittsburgh have discovered a potential treatment for deadly, drug-resistant bacterial infections that uses the same approach that HIV uses to infect cells. ...

Researchers find peptide produced by giant panda fights fungi and bacteria

January 3, 2013
(Medical Xpress)—Researchers working at the Life Sciences College of Nanjing Agricultural University in China have found that giant pandas naturally produce a peptide that can kill fungi and bacteria. In their paper published ...

Synthetic corkscrew peptide kills antibiotic-resistant Gram-negative bacteria

January 24, 2013
An engineered peptide provides a new prototype for killing an entire category of resistant bacteria by shredding and dissolving their double-layered membranes, which are thought to protect those microbes from antibiotics.

Recommended for you

Post-stroke patients reach terra firma with new exosuit technology

July 26, 2017
Upright walking on two legs is a defining trait in humans, enabling them to move very efficiently throughout their environment. This can all change in the blink of an eye when a stroke occurs. In about 80% of patients post-stroke, ...

Molecular hitchhiker on human protein signals tumors to self-destruct

July 24, 2017
Powerful molecules can hitch rides on a plentiful human protein and signal tumors to self-destruct, a team of Vanderbilt University engineers found.

Researchers develop new method to generate human antibodies

July 24, 2017
An international team of scientists has developed a method to rapidly produce specific human antibodies in the laboratory. The technique, which will be described in a paper to be published July 24 in The Journal of Experimental ...

New vaccine production could improve flu shot accuracy

July 24, 2017
A new way of producing the seasonal flu vaccine could speed up the process and provide better protection against infection.

A sodium surprise: Engineers find unexpected result during cardiac research

July 20, 2017
Irregular heartbeat—or arrhythmia—can have sudden and often fatal consequences. A biomedical engineering team at Washington University in St. Louis examining molecular behavior in cardiac tissue recently made a surprising ...

Want to win at sports? Take a cue from these mighty mice

July 20, 2017
As student athletes hit training fields this summer to gain the competitive edge, a new study shows how the experiences of a tiny mouse can put them on the path to winning.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.